LOGIN
Apixaban reduces major bleeding and is non-inferior when compared to enoxaparin for TKA
March 2014
Apixaban reduces major bleeding and is non-inferior when compared to enoxaparin for TKA
Study Type:Meta analysis
OE Level Evidence:1
Journal Level of Evidence:N/A
Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials
Thromb Haemost. 2011 Feb;105(2):245-53Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Data from 3 randomized-controlled trials (7337 individuals) was analyzed to evaluate the efficacy of apixaban in the treatment of TKA complications of venous thromboemolisms (VTE) including deep-vein thrombosis (DVT) and pulmonary embolism (PE), when compared against enoxaparin. Complication incidence was analyzed, along with safety endpoints. The results of the meta-analysis demonstrated that api...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.